Individuals with psychosis and a lifetime history of cannabis use show greater deficits in emotional experience compared to non-using peers

References

• Abi-Dargham A, Gil R, Krystal J, et al. (1998). Increased striatal dopamine transmission in schizophrenia: Confirmation in a second cohort. Am J Psychiatry, 155, 761–7.
   PubMed Web of Science ®Google Scholar
• Abi-Dargham A, Rodenhiser J, Printz D, et al. (2000). Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci, 97, 8104–9.
   PubMed Web of Science ®Google Scholar
• Batalla A, Bhattacharyya S, Yücel M, et al. (2013). Structural and functional imaging studies in chronic cannabis users: A systematic review of adolescent and adult findings. PLoS ONE, 8, e55821.
   PubMed Web of Science ®Google Scholar
• Birchwood M, Smith J, Cochrane R, et al. (1990). The Social Functioning Scale. The development and validation of a new scale of social adjustment for use in family intervention programmes with schizophrenic patients. Br J Psychiatry, 157, 853–9.
   PubMed Web of Science ®Google Scholar
• Bloomfield MA, Morgan CJ, Egerton A, et al. (2014). Dopaminergic function in cannabis users and its relationship to cannabis-induced psychotic symptoms. Biol Psychiatry, 75, 470–8.
   PubMed Web of Science ®Google Scholar
• Boden MT, Gross JJ, Babson KA, Bonn-Miller MO. (2013). The interactive effects of emotional clarity and cognitive reappraisal on problematic cannabis use among medical cannabis users. Addict Behav, 38, 1663–8.
   PubMed Web of Science ®Google Scholar
• Bossong MG, Mehta MA, van Berckel BN, et al. (2015). Further human evidence for striatal dopamine release induced by administration ofΔ 9-tetrahydrocannabinol (THC): Selectivity to limbic striatum. Psychopharmacology, 232, 2723–9.
   PubMed Web of Science ®Google Scholar
• Bossong MG, van Berckel BN, Boellaard R, et al. (2009). Δ9-tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacology, 34, 759–66.
   PubMed Web of Science ®Google Scholar
• Bovasso GB. (2001). Cannabis abuse as a risk factor for depressive symptoms. Am J Psychiatry, 158, 2033–7.
   PubMed Web of Science ®Google Scholar
• Buck B, Lysaker PH. (2013). Consummatory and anticipatory anhedonia in schizophrenia: Stability, and associations with emotional distress and social function over six months. Psychiatry Res, 205, 30–5.
   PubMed Web of Science ®Google Scholar
• Burns T, Patrick D. (2007). Social functioning as an outcome measure in schizophrenia studies. Acta Psychiatr Scand, 116, 403–18.
   PubMed Web of Science ®Google Scholar
• Cassidy CM, Brodeur MB, Lepage M, Malla A. (2014a). Do reward-processing deficits in schizophrenia-spectrum disorders promote cannabis use? An investigation of physiological response to natural rewards and drug cues. J Psychiatry Neurosci, 39, 339.
   PubMed Web of Science ®Google Scholar
• Cassidy CM, Lepage M, Harvey P-O, Malla A. (2012). Cannabis use and anticipatory pleasure as reported by subjects with early psychosis and community controls. Schizophr Res, 137, 39–44.
   PubMed Web of Science ®Google Scholar
• Cassidy CM, Lepage M, Malla A. (2014b). Do motivation deficits in schizophrenia-spectrum disorders promote cannabis use? An investigation of behavioural response to natural rewards and drug cues. Psychiatry Res, 215, 522–7.
   PubMed Web of Science ®Google Scholar
• Chan RC, Wang Y, Huang J, et al. (2010). Anticipatory and consummatory components of the experience of pleasure in schizophrenia: Cross-cultural validation and extension. Psychiatry Res, 175, 181–3.
   PubMed Web of Science ®Google Scholar
• CORP I. (2013). IBM SPSS Statistics for Windows. Version 22.0. Armonk, NY: IBM Corp.
   Google Scholar
• D’Souza DC, Abi-Saab WM, Madonick S, et al. (2005). Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction. Biol Psychiatry, 57, 594–608.
   PubMed Web of Science ®Google Scholar
• Dawes GM, Sitharthan T, Conigrave KM, et al. (2011). Patients admitted for inpatient cannabis detoxification: Withdrawal symptoms and impacts of common comorbidities. J Subst Use, 16, 392–405.
   Web of Science ®Google Scholar
• Dorard G, Berthoz S, Phan O, et al. (2008). Affect dysregulation in cannabis abusers: A study in adolescents and young adults. Eur Child Adolesc Psychiatry, 17, 274–82.
   PubMed Web of Science ®Google Scholar
• First M, Spitzer R, Gibbon M, Williams J. (1995). Structured clinical interview of DSM-IV Axis I Disorders (SCID-I): Patient edition. Version 2. New York: New York State Psychiatric Institute, Biometrics Research Department.
   Google Scholar
• Fischer AS, Whitfield-Gabrieli S, Roth RM, et al. (2014). Impaired functional connectivity of brain reward circuitry in patients with schizophrenia and cannabis use disorder: Effects of cannabis and THC. Schizophr Res, 158, 176–82.
   PubMed Web of Science ®Google Scholar
• Frost KH, Strauss GP. (2016). A review of anticipatory pleasure in schizophrenia. Curr Behav Neurosci Rep, 3, 232–47.
   PubMedGoogle Scholar
• Gard DE, Fisher M, Garrett C, et al. (2009). Motivation and its relationship to neurocognition, social cognition, and functional outcome in schizophrenia. Schizophr Res, 115, 74–81.
   PubMed Web of Science ®Google Scholar
• Gard DE, Gard MG, Kring AM, John OP. (2006). Anticipatory and consummatory components of the experience of pleasure: A scale development study. J Res Personal, 40, 1086–102.
   Web of Science ®Google Scholar
• Gard DE, Kring AM, Gard MG, et al. (2007). Anhedonia in schizophrenia: Distinctions between anticipatory and consummatory pleasure. Schizophr Res, 93, 253–60.
   PubMed Web of Science ®Google Scholar
• Gard DE, Sanchez AH, Cooper K, et al. (2014). Do people with schizophrenia have difficulty anticipating pleasure, engaging in effortful behavior, or both. J Abnorm Psychol, 123, 771–82.
   PubMed Web of Science ®Google Scholar
• Grech A, Van Os J, Jones PB, et al. (2005). Cannabis use and outcome of recent onset psychosis. Eur Psychiatry, 20, 349–53.
   PubMed Web of Science ®Google Scholar
• Green AI, Tohen MF, Hamer RM, et al. (2004). First episode schizophrenia-related psychosis and substance use disorders: Acute response to olanzapine and haloperidol. Schizophr Res, 66, 125–35.
   PubMed Web of Science ®Google Scholar
• Gruber SA, Rogowska J, Yurgelun-Todd DA. (2009). Altered affective response in marijuana smokers: An FMRI study. Drug Alcohol Depend, 105, 139–53.
   PubMed Web of Science ®Google Scholar
• Hayes AF. (2013). Introduction to mediation, moderation, and conditional process analysis: A regression-based approach. New York: Guilford Press.
   Google Scholar
• Kay SR, Fiszbein A, Opler LA. (1987). The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull, 13, 261–76.
   PubMed Web of Science ®Google Scholar
• Koskinen J, Löhönen J, Koponen H, et al. (2010). Rate of cannabis use disorders in clinical samples of patients with schizophrenia: A meta-analysis. Schizophr Bull, 36, 1115–30.
   PubMed Web of Science ®Google Scholar
• Kring AM, Barch DM. (2014). The motivation and pleasure dimension of negative symptoms: Neural substrates and behavioral outputs. Eur Neuropsychopharmacol, 24, 725–36.
   PubMed Web of Science ®Google Scholar
• Kring AM, Moran EK. (2008). Emotional response deficits in schizophrenia: Insights from affective science. Schizophr Bull, 34, 819–34.
   PubMed Web of Science ®Google Scholar
• Kring AM, Smith DA, Neale JM. (1994). Individual differences in dispositional expressiveness: Development and validation of the Emotional Expressivity Scale. J Personal Soc Psychol, 66, 934.
   PubMed Web of Science ®Google Scholar
• Lawn W, Freeman TP, Pope RA, et al. (2016). Acute and chronic effects of cannabinoids on effort-related decision-making and reward learning: An evaluation of the cannabis ‘amotivational’ hypotheses. Psychopharmacology, 233, 3537–52.
   PubMed Web of Science ®Google Scholar
• McLellan AT, Luborsky L, Woody GE, O’Brien CP. (1980). An improved diagnostic evaluation instrument for substance abuse patients: The Addiction Severity Index. J Nerv Ment Dis, 168, 26–33.
   PubMed Web of Science ®Google Scholar
• McPartland JM, Duncan M, Di Marzo V, Pertwee RG. (2015). Are cannabidiol and Δ9‐tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. Br J Pharmacol, 172, 737–53.
   PubMed Web of Science ®Google Scholar
• Nestor L, Hester R, Garavan H. (2010). Increased ventral striatal BOLD activity during non-drug reward anticipation in cannabis users. Neuroimage, 49, 1133–43.
   PubMed Web of Science ®Google Scholar
• Shollenbarger SG, Price J, Wieser J, Lisdahl K. (2015). Poorer frontolimbic white matter integrity is associated with chronic cannabis use, FAAH genotype, and increased depressive and apathy symptoms in adolescents and young adults. NeuroImage: Clin, 8, 117–25.
   PubMed Web of Science ®Google Scholar
• Troisi A, Pasini A, Saracco M, Spalletta G. (1998). Psychiatric symptoms in male cannabis users not using other illicit drugs. Addiction, 93, 487–92.
   PubMed Web of Science ®Google Scholar
• van de Giessen E, Weinstein JJ, Cassidy CM, et al. (2017). Deficits in striatal dopamine release in cannabis dependence. Mol Psychiatry, 22, 68–75.
   PubMed Web of Science ®Google Scholar
• van Hell HH, Vink M, Ossewaarde L, et al. (2010). Chronic effects of cannabis use on the human reward system: An fMRI study. Eur Neuropsychopharmacol, 20, 153–63.
   PubMed Web of Science ®Google Scholar
• Van Mastrigt S, Addington J, Addington D. (2004). Substance misuse at presentation to an early psychosis program. Soc Psychiatry Psychiatr Epidemiol, 39, 69–72.
   PubMed Web of Science ®Google Scholar
• Voruganti LN, Slomka P, Zabel P, et al. (2001). Cannabis induced dopamine release: An in-vivo SPECT study. Psychiatry Res: Neuroimag, 107, 173–7.
   PubMed Web of Science ®Google Scholar
• Wilcockson T, Sanal N. (2016). Heavy cannabis use and attentional avoidance of anxiety-related stimuli. Addict Behav Rep, 3, 38–42.
   PubMedGoogle Scholar
• Wise RA. (2002). Brain reward circuitry: Insights from unsensed incentives. Neuron, 36, 229–40.
   PubMed Web of Science ®Google Scholar